Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model [PDF]
, 2002 Isabelle Renard +6 more
openalex +1 more source
The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC
VIEW, EarlyView.Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li +10 more
wiley +1 more source
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer [PDF]
, 2003 Roland Repp +14 more
openalex +1 more source
Allergy, EarlyView.SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy +17 more
wiley +1 more source
Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors [PDF]
, 2003 Nina Jendreyko +6 more
openalex +1 more source
Tumour progression shows decrease in PD‐L1 expression in matched metastases/primary uveal melanomas
Acta Ophthalmologica, EarlyView.Abstract Purpose Immune checkpoint inhibitors (ICI) have revolutionised the treatment of several malignancies. However, the results of ICI therapy remain unsatisfactory in metastatic uveal melanoma (UM). We analysed the expression of PD1, PD‐L1, T‐cell and macrophage markers in a set of matched primary and metastatic UM in an attempt to better ...
Maria Chiara Gelmi +5 more
wiley +1 more source
A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killing [PDF]
, 2003 Ludger Große‐Hovest +5 more
openalex +1 more source
British Journal of Haematology, EarlyView.A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo +24 more
wiley +1 more source
T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites [PDF]
, 2003 Shigeto Yoshida +6 more
openalex +1 more source
British Journal of Haematology, EarlyView.Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia +11 more
wiley +1 more source